4.7 Article

Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway

期刊

DIABETOLOGIA
卷 56, 期 11, 页码 2456-2466

出版社

SPRINGER
DOI: 10.1007/s00125-013-3028-4

关键词

Beta cell apoptosis; Exendin-4; G-protein-coupled receptor 40; JNK; p38 MAPK; Palmitate

资金

  1. Ministero dell'Universita e della Ricerca, Italy

向作者/读者索取更多资源

The mechanisms of the protective effects of exendin-4 on NEFA-induced beta cell apoptosis were investigated. The effects of exendin-4 and palmitate were evaluated in human and murine islets, rat insulin-secreting INS-1E cells and murine glucagon-secreting alpha-TC1-6 cells. mRNA and protein expression/phosphorylation were measured by real-time RT-PCR and immunoblotting or immunofluorescence, respectively. Small interfering (si)RNAs for Ib1 and Gpr40 were used. Cell apoptosis was quantified by two independent assays. Insulin release was assessed with an insulin ELISA. Exposure of human and murine primary islets and INS-1E cells, but not alpha-TC1-6 cells, to exendin-4 inhibited phosphorylation of the stress kinases, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK), and prevented apoptosis in response to palmitate. Exendin-4 increased the protein content of islet-brain 1 (IB1), an endogenous JNK blocker; however, siRNA-mediated reduction of IB1 did not impair the ability of exendin-4 to inhibit JNK and prevent apoptosis. Exendin-4 reduced G-protein-coupled receptor 40 (GPR40) expression and inhibited palmitate-induced phosphorylation of mitogen-activated kinase kinase (MKK)4 and MKK7. The effects of exendin-4 were abrogated in the presence of the protein kinase A (PKA) inhibitors, H89 and KT5720. Knockdown of GPR40, as well as use of a specific GPR40 antagonist, resulted in diminished palmitate-induced JNK and p38 MAPK phosphorylation and apoptosis. Furthermore, inhibition of JNK and p38 MAPK activity prevented palmitate-induced apoptosis. Exendin-4 counteracts the proapoptotic effects of palmitate in beta cells by reducing GPR40 expression and inhibiting MKK7- and MKK4-dependent phosphorylation of the stress kinases, JNK and p38 MAPK, in a PKA-dependent manner.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics

Philip D. Home, Rory J. McCrimmon, Julio Rosenstock, Matthias Bluher, Katrin Pegelow, Lydie Melas-Melt, Khier Djaballah, Francesco Giorgino

Summary: The aim of this study was to investigate the impact of baseline participant characteristics on the outcomes of the SoliMix study. The findings showed that the treatment effects of iGlarLixi were consistent across various baseline characteristics, supporting its use as an effective and well-tolerated treatment option for people with type 2 diabetes.

DIABETES OBESITY & METABOLISM (2023)

Review Endocrinology & Metabolism

Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta-analysis

Sergio Di Molfetta, Irene Caruso, Angelo Cignarelli, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino

Summary: This study aimed to evaluate the effect of professional continuous glucose monitoring (p-CGM)-based care on glucose control in type 1 and type 2 diabetes patients. The use of p-CGM was found to significantly reduce glycated haemoglobin (HbA1c) levels without increasing hypoglycaemia compared to standard care.

DIABETES OBESITY & METABOLISM (2023)

Review Endocrinology & Metabolism

Glucagon in type 2 diabetes: Friend or foe?

Irene Caruso, Nicola Marrano, Giuseppina Biondi, Valentina Annamaria Genchi, Rossella D'Oria, Gian Pio Sorice, Sebastio Perrini, Angelo Cignarelli, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino

Summary: Hyperglucagonemia contributes to the pathogenesis of type 2 diabetes and its complications. Glucagon regulates glucose homeostasis and can affect weight, liver disease, peripheral neuropathy, and retinopathy. However, its role in diabetic nephropathy and cardiovascular system is uncertain. This review aims to summarize the current understanding and calls for further research on modulating glucagon signaling for new antidiabetic drugs.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2023)

Review Biochemistry & Molecular Biology

Type 2 Diabetes and Alzheimer's Disease: The Emerging Role of Cellular Lipotoxicity

Nicola Marrano, Giuseppina Biondi, Anna Borrelli, Martina Rella, Tommaso Zambetta, Ludovico Di Gioia, Mariangela Caporusso, Giancarlo Logroscino, Sebastio Perrini, Francesco Giorgino, Annalisa Natalicchio

Summary: Type 2 diabetes and Alzheimer's disease are major health issues with a close relationship. Lipotoxicity may be the missing link connecting the pathogenesis of these two diseases. Obesity, the main cause of lipotoxicity, is a major risk factor for both conditions. This review provides a comprehensive overview of the common molecular pathways activated by lipotoxicity in type 2 diabetes and Alzheimer's disease, suggesting potential new therapeutic perspectives.

BIOMOLECULES (2023)

Article Endocrinology & Metabolism

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

Sue D. D. Pedersen, Francesco Giorgino, Guillermo Umpierrez, Vivian T. T. Thieu, Angel Rodriguez, Claudia Nicolay, Laura Fernandez Lando, Chrisanthi A. A. Karanikas, Jacek Kiljanski

Summary: This study assessed the relationship between HbA1c and body weight reductions in tirzepatide treatment. In the SURPASS clinical trials, significant reductions in HbA1c were observed for participants treated with tirzepatide at all doses, and weight loss was associated with these reductions. Furthermore, a modest but statistically significant association between HbA1c and body weight changes was observed in several trials, indicating that both weight-independent and weight-dependent mechanisms contribute to the improvement in glycaemic control induced by tirzepatide.

DIABETES OBESITY & METABOLISM (2023)

Review Endocrinology & Metabolism

Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials

Andrea Iannone, Patrizia Natale, Suetonia C. Palmer, Antonio Nicolucci, Maria Rendina, Francesco Giorgino, Luigi Laviola, Alfredo Di Leo, Giovanni F. M. Strippoli

Summary: A systematic review found that drugs approved for weight management in adults with obesity or overweight were more effective in reducing body weight and waist circumference compared to other drugs, with no significant differences in cardiovascular death risk.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study

Raffaele Napoli, Cesare Berra, Andrei-Mircea Catarig, Chiara Di Loreto, Emily Donatiello, Tina Landsvig Berentzen, Dario Pitocco, Francesco Giorgino

Summary: The SURE Italy study investigated the use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice. The study found that this treatment method led to significant improvements in glycated hemoglobin, body weight, and other outcomes, with a good safety profile.

DIABETES OBESITY & METABOLISM (2023)

Review Endocrinology & Metabolism

New insights into the treatment of obesity

Matthias Blueher, Mohini Aras, Louis J. Aronne, Rachel L. Batterham, Francesco Giorgino, Linong Ji, Kirsi H. Pietilainen, Oliver Schnell, Elena Tonchevska, John P. H. Wilding

Summary: Obesity is a chronic disease with increasing prevalence worldwide and is associated with various health risks. The treatment of obesity includes behavioral interventions, pharmacotherapy, and bariatric surgery, but long-term weight maintenance is challenging. Recent advances in understanding the pathophysiology of obesity have led to the development of novel and effective therapies, such as semaglutide and tirzepatide, which have shown promising weight loss effects and improvement in cardiometabolic risk factors. These new agents may bridge the gap between traditional treatments and achieve better outcomes in obesity management.

DIABETES OBESITY & METABOLISM (2023)

Review Endocrinology & Metabolism

Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis

Gabriella Garruti, Jacek Baj, Angelo Cignarelli, Sebastio Perrini, Francesco Giorgino

Summary: Current perspectives suggest that an impaired balance, fetal malnutrition, and exposure to endocrine-disrupting compounds contribute to obesity and impaired insulin function. Additionally, the liver plays a crucial role in maintaining glucose balance through hepatokines, bile acids, and ketone bodies. Recent studies have revealed that bile acids and ketone bodies act as endocrine molecules that regulate key metabolic pathways and mediate inflammation and oxidative stress. This review focuses on the role of hepatokines, bile acids, and ketone bodies in obesity, diabetes prevention and management, and explores their potential as therapeutic approaches for metabolic and aging-related diseases.

FRONTIERS IN ENDOCRINOLOGY (2023)

Article Endocrinology & Metabolism

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes

Francesco Giorgino, Bruno Guerci, Martin Fuechtenbusch, Jeremie Lebrec, Kristina Boye, Marco Orsini Federici, Elke Heitmann, Anne Dib, Maria Yu, Helene Sapin, Luis-Emilio Garcia-Perez

Summary: The TROPHIES study presented the final results, indicating that patients initiating dulaglutide had a longer duration without significant treatment changes and higher treatment persistence compared to those initiating liraglutide. Both drugs showed similar and clinically meaningful reductions in glycated haemoglobin (HbA1c) and weight.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months

Kristina S. Boye, Jeremie Lebrec, Anne Dib, Elke Heitmann, Marco Orsini Federici, Maria Yu, Helene Sapin, Annabel Barrett, Bruno Guerci, Francesco Giorgino, Martin Fuechtenbusch, Luis-Emilio Garcia-Perez

Summary: This study reports the health-related patient-reported outcomes (PROs) of patients with T2D initiating their first injectable glucose-lowering medication (GLM) with two common GLP-1RAs. The results show that dulaglutide had more significant improvements in PRO scores compared to liraglutide, and patients were more satisfied with the injection device of dulaglutide.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Evaluation of a digital tool supporting therapeutic decision making for the personalized management of patients with type 2 diabetes not treated with insulin: A pilot study

Sergio Di Molfetta, Luigi Laviola, Annalisa Natalicchio, Anna Leonardini, Angelo Cignarelli, Erminio Bonizzoni, Elena Acmet, Francesco Giorgino

Summary: The study investigates the benefits of using the Personalized Treatment Tool (PTT) in managing non-insulin treated type 2 diabetes patients. The PTT assists diabetologists in evaluating patients' clinical characteristics and self-monitoring blood glucose data. Results show significant improvements in glucose control and variability in patients using the PTT.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Article Andrology

The chronic alcohol consumption influences the gonadal axis in men: Results from a meta-analysis

Daniele Santi, Angelo Cignarelli, Matteo Baldi, Andrea Sansone, Giorgia Spaggiari, Manuela Simoni, Giovanni Corona

Summary: This meta-analysis found that alcohol consumption is associated with a significant reduction in total testosterone, free testosterone, and sex hormone binding globulin levels in healthy men. It also found an increase in estradiol levels. However, these effects were only observed in men with chronic alcohol consumption and not in those with recognized alcohol use disorder or after acute alcohol intake.

ANDROLOGY (2023)

暂无数据